http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020528900-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5578
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
filingDate 2018-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2020528900-A
titleOfInvention Prostacyclin receptor agonist for body fat reduction
abstract It has been shown that prostacyclin (PGI 2 ) analogs, which are agonists of the prostacyclin receptor (PI), activate lipolytic activity in adipocytes. Pharmaceutical compositions and pharmaceutical compositions that use PGI 2 receptor agonists to reduce subcutaneous adiposium and treat or reduce symptoms of obesity-related diseases or disorders such as diabetes, fatty liver disease and cardiovascular disease. The method is also described.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7313644-B1
priorityDate 2017-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9911469
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426152062

Total number of triples: 33.